Trials / Completed
CompletedNCT00583544
A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers
A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Targacept Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TC-2216 | Multiple ascending dose groups will be explored. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-01-01
- Completion
- 2008-02-01
- First posted
- 2007-12-31
- Last updated
- 2008-07-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00583544. Inclusion in this directory is not an endorsement.